… approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and
Pancreatic Cancer. Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor …

… These findings suggest that erlotinib is important for first-line treatment of patients with advanced
EGFR mutation… Screening for epidermal growth factor receptor mutations in lung cancer. …

… growth factors that includes transforming growth factor (TGF), amphiregulin, heparin binding
EGF and β-cellulin. TGFα is one growth factor … showed that treatment with erlotinib induced …

… Diarrhea and skin rash are the principal toxicities of erlotinib, and they preclude treatment
at doses higher than 150 mg/d on an uninterrupted protracted oral schedule in patients with …

… In summary, the present study is the first case report of PSC successfully treated using
erlotinib. The findings suggest that erlotinib is a viable therapeutic option for patients with PSC …

… erlotinib. Extracellular binding of ligands such as the epidermal growth factor (EGF) and
transforming growth factor-… survival, 31 % of patients treated with erlotinib in this study were alive …

… [3]Recognition that overexpression of the epidermal growth factor receptor (EGFR) occurs in
a high … In the phase III placebo-controlled trial, patients treated with erlotinib experienced a …

… mutations in epidermal growth factor receptors (EGFR) are … leads to the failure of treatment.
The most common mechanism … that treatment with both Cetuximab and Erlotinib significantly …

… combined growth inhibitory effect of erlotinib and R428 on HN5-ER cell signaling pathways,
we evaluated P-Akt levels in cells treated with the same ineffective concentrations of erlotinib…

… to be maintained on erlotinib treatment at the lowest dose that keeps them in remission, as
long as no considerable adverse effects are observed. Treatment resistance, as observed in …